Drug shortage: Liraglutide Injection (LIRAGLUTIDE, VICTOZA, SAXENDA)
FDA lists 11 presentations as Current. Availability: Limited Availability (3), Available (6). Reason: Delay in shipping of the drug; Discontinuation of the manufacture of the drug. Companies: Novo Nordisk, Inc., Meitheal Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals USA, Inc..
- Published by source
- 2023-07-18
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Novo Nordisk, Inc.
- Products
- Liraglutide Injection LIRAGLUTIDE VICTOZA SAXENDA
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Limited Availability
Remedy / actions:
- Distributed by Teva
- Estimated shortage duration: TBD
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2023-07-18
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #903 | new | 2026-10-22 | b158195b99af…2351e4 | 748f6514da15…9470a9 |
Chain head: #1094 edf3be25ec2e…478842